Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.47 |
| ▸ | JAK1 | P23458 | 10/20 | 0.47 |
| ▸ | WNT3A | P56704 | 2/20 | 0.42 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25410990 | 0.86 | JAK2 (0.43) | JAK2JAK1WNT3AEIF2AK4RET | |
| SCHEMBL29656913 | 0.78 | MAP4K4 (0.48) | EIF2AK4MAP4K4RETGPR119HDAC1 | |
| SCHEMBL12811247 | 0.76 | EGLN2 (0.48) | JAK2JAK1WNT3AEIF2AK4RET | |
| SCHEMBL29967507 | 0.75 | WNT3A (0.48) | JAK2JAK1WNT3AMAP4K4GPR119 | |
| SCHEMBL23410408 | 0.75 | WNT3A (0.48) | JAK2JAK1WNT3AMAP4K4GPR119 | |
| SCHEMBL22165640 | 0.75 | RET (0.49) | EIF2AK4MAP4K4RETGPR119 | |
| SCHEMBL29461416 | 0.74 | GPR119 (0.46) | EIF2AK4RETGPR119 | |
| SCHEMBL25406872 | 0.73 | JAK2 (0.41) | JAK2JAK1MAP4K4RETGPR119 | |
| SCHEMBL23410444 | 0.73 | PDE10A (0.44) | JAK2JAK1WNT3AGPR119 | |
| SCHEMBL23410586 | 0.73 | MAPT (0.52) | JAK2JAK1WNT3AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | UTRN, ZFX, CBX6 | JAK2 4802/4885JAK1 4777/4885WNT3A 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.